NewSquare Capital’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

NewSquare Capital’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-100	Closed	-$89	–	968
2022 Q4	$89	Buy	+100	New	+$133	﹤0.01%	774
2020 Q3	–	Sell	-550	Closed	-$3K	–	419
2020 Q2	$3K	Buy	+550	New	+$2.11K	﹤0.01%	301

Other funds holding SRNE

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return

Crescent Grove Advisors Lake Forest, Illinois $1.04B AUM 17.78% 1-Year Est. Return

Lattice Capital Management Kirkland, Washington $56.9M AUM 49.15% 1-Year Est. Return

S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return

GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return

Houlihan Financial Resource Group Ashburn, Virginia $257M AUM 14.19% 1-Year Est. Return

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return

Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

NewSquare Capital's SRNE Position: Q1 2023 in Review

NewSquare Capital sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 100 shares — an estimated $89 sold.

NewSquare Capital first reported a position in SRNE in Q2 2020 and held it in 2 quarters. The position peaked at $3K in Q2 2020. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

NewSquare Capital reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
NewSquare Capital sold 100 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $89.
NewSquare Capital first reported a position in Sorrento Therapeutics, Inc. in Q2 2020 and held it in 2 quarters.
NewSquare Capital's Sorrento Therapeutics, Inc. position peaked at $3K in Q2 2020.
34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on NewSquare Capital's 13F filing for Q1 2023, filed 1 May 2023.